Cart 0

MarketsandMarkets

Biosurgery Market - Forecast to 2021

$5,650.00

Report Published By: MarketsandMarkets
Publication Date : Nov-16
No. Of Pages: 266

The “BIOSURGERY MARKET BY PRODUCT (FIBRIN & COLLAGEN SEALANT, HEMOSTATS, ADHESION BARRIERS, BIOLOGICAL MESHS, SOFT TISSUE ATTACHMENTS, STAPLER, BONE GRAFT SUBSTITUES) BY APPLICATION (ORTHOPEDIC, GYNECOLOGY, CARDIOVASCULAR, RECONSTRUCTIVE)
FORECAST TO 2021”

The global biosurgery market is expected to grow at a CAGR of 8.8% during the forecast period of 2016 to 2021. The market is poised to reach USD 27.78 billion by 2021 from USD 18.21 billion in 2016. The market is primarily driven by rising number of surgeries, rising incidences of sports related injuries and spinal problems, increasing clearance of biosurgery products by regulatory authorities, and rising need of effective blood loss management.

In this report, the biosurgery market is segmented on the basis of product type, application, and geography. On the basis of product type, the market is primarily segmented into surgical sealants, hemostatic agents, adhesion barriers, bone graft substitutes, and staple line reinforcement agents. The bone graft substitute market is further sub-segmented into bone-allografts, demineralized bone matrix, bone morphogenetic proteins, and synthetic bone-grafts. The surgical sealants market on the other hand is segmented into natural and synthetic/semi-synthetic sealants. On the basis of application, the market is sub-segmented into neurological surgeries, general surgeries, orthopaedic surgeries, thoracic surgeries, cardiovascular surgeries, gynaecological surgeries, urology surgeries, and reconstructive surgeries.

In 2015, the soft tissue attachments segment accounted for the largest share of the global biosurgery products market. This is majorly attributed to the rampant use of soft tissue patches across different types of surgeries. This segment will continue to dominate the biosurgery products market by 2021, mainly due to the rising demand of these products from emerging countries and widening of application areas of soft tissue repair products across surgical procedures.

On the basis of geography, the North American market accounted for the largest share of the global biosurgery market, followed by Europe, Asia-Pacific, Latin America, and Middle East and Africa in 2015. The Asia-Pacific region is expected to be the fastest growing region during the forecast period, due to rising health awareness, growth in per capita income, and improving healthcare infrastructure in the region.

Some of the key players operating in this market include Baxter International Inc. (U.S.), C.R. Bard, Inc. (U.S.), Johnson & Johnson (U.S.), Covidien plc. (Ireland), Getinge Group (Sweden), B. Braun Melsungen AG (Germany), Cryolife Inc. (U.S.), Stryker Corporation (U.S.), Hemostasis, LLC. (U.S.), and Sanofi Group (France).
Research Coverage
? Detailed insights on all the submarkets, based on product (sealants, hemostatic agents, adhesion barriers, soft-tissue attachments, bone graft substitutes, and staple line reinforcement agents), this can help market players to identify high growth segments in the biosurgery market.

? The report also provides information on key players in this market and their growth strategies and recent developments. This can help the company to assess the competition at global and regional levels in a better manner.

? Key insights and market sizing for the different applications of the biosurgery market namely, neurological surgeries, cardiovascular surgeries, general surgeries, orthopedic surgeries, thoracic surgeries, gynecology surgeries, urology surgeries, and reconstruction surgeries.

? Country-wise market size and forecast for all the sub segments. Thus, not only the high growth application and end user areas; the market size numbers provided in the report will also enable market players to identify key geographic markets, and thereby strategize global marketing efforts in order to achieve sustainable revenue growth in the coming years.

? It provides key insights on market dynamics, such as drivers, restraints, opportunities, and challenges for this market.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms, and allow them to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report could use one or a combination of the below-mentioned strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for increasing their market shares.
The report provides insights on the following pointers:
? Market Penetration: Comprehensive information on the product portfolios offered by top players in the biosurgery market. The report analyzes the biosurgery products market by product type, application, and region
? Product Development/Innovation: Detailed insights on upcoming trends, research and development activities, and new product launches in the biosurgery market
? Market Development: Comprehensive information about lucrative emerging markets by product and region
? Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the biosurgery market
? Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and manufacturing capabilities of leading players in the biosurgery market

TABLE OF CONTENTS

1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.3 MARKET SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 YEARS CONSIDERED FOR THE STUDY 27
1.4 CURRENCY 27
1.5 LIMITATIONS 27
1.6 STAKEHOLDERS 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
2.1.1 SECONDARY DATA 29
2.1.1.1 Key data from secondary sources 29
2.1.2 PRIMARY DATA 30
2.1.2.1 Key data from primary sources 30
2.1.2.2 Key industry insights 31
2.2 MARKET SIZE ESTIMATION 31
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 33
2.4 MARKET SHARE ESTIMATION 34
2.5 ASSUMPTIONS FOR THE STUDY 34
3 EXECUTIVE SUMMARY 35
4 PREMIUM INSIGHTS 40
4.1 BIOSURGERY PRODUCTS: MARKET OVERVIEW 40
4.2 ASIA-PACIFIC: NATURAL/BIOLOGICAL SEALANTS MARKET, BY TYPE (2015) 41
4.3 GEOGRAPHIC SNAPSHOT OF THE BIOSURGERY PRODUCTS MARKET 42
4.4 REGIONAL MIX OF THE BIOSURGERY PRODUCTS MARKET 43
4.5 BIOSURGERY PRODUCTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 43
5 MARKET OVERVIEW 44
5.1 INTRODUCTION 45
5.2 MARKET DYNAMICS 45
5.2.1 MARKET DRIVERS 46
5.2.1.1 Rising number of surgeries 46
5.2.1.2 Approval of a number of new and advanced biosurgery products
by regulatory authorities 46
?
5.2.1.3 Increasing incidence of sports-related injuries and spinal Ailments 47
5.2.1.4 Increasing focus on effective blood loss management in patients during surgeries 47
5.2.2 MARKET RESTRAINT 48
5.2.2.1 Unfavorable reimbursement scenario for biosurgery products 48
5.2.3 MARKET OPPORTUNITY 49
5.2.3.1 Improving healthcare systems in emerging markets 49
5.2.4 MARKET CHALLENGE 50
5.2.4.1 Requirement of skilled personnel for effective use of biosurgery products 50
6 INDUSTRY INSIGHTS 51
6.1 INTRODUCTION 51
6.2 INDUSTRY TRENDS 51
6.2.1 GROWING PREFERENCE FOR BIOLOGICAL MESHES IN SURGICAL PROCEDURES 52
6.2.2 INTRODUCTION OF NEW TECHNOLOGIES IN THE BIOSURGERY PRODUCTS MARKET 52
6.2.3 GROWTH IN THE NUMBER OF ACQUISITIONS IN THE BIOSURGERY PRODUCTS MARKET 53
6.3 REGULATORY ANALYSIS 54
6.3.1 NORTH AMERICA 54
6.3.1.1 U.S. 54
6.3.1.2 Canada 55
6.3.2 EUROPE 56
6.3.3 APAC 57
6.3.3.1 Japan 57
6.3.3.2 China 58
6.3.3.3 India 58
6.4 VENDOR BENCHMARKING 59
7 BIOSURGERY PRODUCTS MARKET, BY TYPE 62
7.1 INTRODUCTION 63
7.2 SEALANTS 64
7.2.1 NATURAL/BIOLOGICAL SEALANTS 66
7.2.1.1 Natural/biological sealants, by type 67
7.2.1.1.1 Fibrin sealants 68
7.2.1.1.2 Gelatin-based sealants 69
7.2.1.1.3 Collagen-based sealants 71
7.2.1.1.4 Other natural sealants 72
7.2.1.2 Natural/biological sealants, by origin 73
7.2.1.2.1 Human blood-based sealants 74
7.2.1.2.2 Animal-based sealants 75
?
7.2.2 SYNTHETIC AND SEMI-SYNTHETIC SEALANTS 76
7.2.2.1 Cyanoacrylates 77
7.2.2.2 Polymeric hydrogels 79
7.2.2.3 Urethane-based sealants 80
7.2.2.4 Other synthetic and semi-synthetic sealants 82
7.3 HEMOSTATIC AGENTS 83
7.4 ADHESION BARRIERS 84
7.4.1 SYNTHETIC ADHESION BARRIERS 85
7.4.1.1 Regenerated cellulose 87
7.4.1.2 Hyaluronic acid (HA) 88
7.4.1.3 Polyethylene glycol (PEG) 89
7.4.1.4 Others 90
7.4.2 NATURAL ADHESION BARRIERS 91
7.4.2.1 Fibrin-based adhesion barriers 93
7.4.2.2 Collagen & protein 94
7.5 SOFT TISSUE ATTACHMENTS (PATCH/MESH) 95
7.5.1 SYNTHETIC MESHES 96
7.5.2 BIOLOGICAL MESHES 98
7.5.2.1 Allografts 99
7.5.2.2 Xenografts 101
7.6 BONE GRAFT SUBSTITUTES 102
7.6.1 BONE ALLOGRAFTS 103
7.6.2 DEMINERALIZED BONE MATRIX (DBM) 104
7.6.3 BONE MORPHOGENETIC PROTEINS (BMP) 105
7.6.4 SYNTHETIC BONE GRAFTS 106
7.7 STAPLE LINE REINFORCEMENT AGENTS 107
8 BIOSURGERY PRODUCTS MARKET, BY APPLICATION 109
8.1 INTRODUCTION 110
8.2 ORTHOPEDIC SURGERIES 111
8.3 GENERAL SURGERIES 113
8.4 NEUROLOGICAL SURGERIES 114
8.5 CARDIOVASCULAR SURGERIES 115
8.6 RECONSTRUCTIVE SURGERIES 117
8.7 GYNECOLOGICAL SURGERIES 118
8.8 UROLOGICAL SURGERIES 120
8.9 THORACIC SURGERIES 121
?
9 BIOSURGERY PRODUCTS MARKET, BY REGION 123
9.1 INTRODUCTION 124
9.2 NORTH AMERICA 126
9.2.1 U.S. 132
9.2.2 CANADA 137
9.3 EUROPE 142
9.3.1 GERMANY 149
9.3.2 U.K. 154
9.3.3 FRANCE 159
9.3.4 ITALY 164
9.3.5 SPAIN 169
9.3.6 REST OF EUROPE (ROE) 174
9.4 ASIA-PACIFIC (APAC) 179
9.4.1 JAPAN 186
9.4.2 CHINA 191
9.4.3 INDIA 196
9.4.4 REST OF ASIA-PACIFIC (ROAPAC) 201
9.5 LATIN AMERICA 206
9.5.1 BRAZIL 211
9.5.2 MEXICO 216
9.5.3 REST OF LATIN AMERICA 221
9.6 MIDDLE EAST AND AFRICA 226
10 COMPETITIVE LANDSCAPE 232
10.1 OVERVIEW 232
10.2 MARKET SHARE ANALYSIS 234
10.2.1 SEALANTS AND HEMOSTATIC AGENTS 234
10.2.2 BONE GRAFT SUBSTITUTES 236
10.2.3 ADHESION BARRIERS 237
10.3 COMPETITIVE SITUATIONS AND TRENDS 238
10.3.1 AGREEMENTS AND COLLABORATIONS 239
10.3.2 PRODUCT LAUNCHES 240
10.3.3 ACQUISITIONS 240
10.3.4 EXPANSIONS 241
10.3.5 OTHER DEVELOPMENTS 242
?
11 COMPANY PROFILES 243
(Overview, Products and Services, Financials, Strategy & Development)*
11.1 INTRODUCTION 243
11.2 BAXTER INTERNATIONAL INC. 244
11.3 C.R. BARD, INC. 247
11.4 COVIDIEN PLC (A SUBSIDIARY OF MEDTRONIC, INC.) 250
11.5 JOHNSON & JOHNSON SERVICES, INC. 253
11.6 SANOFI GROUP 256
11.7 ATRIUM MEDICAL CORPORATION (A PART OF GETINGE GROUP) 258
11.8 B. BRAUN MELSUNGEN AG 260
11.9 CRYOLIFE, INC. 262
11.10 STRYKER CORPORATION 264
11.11 HEMOSTASIS, LLC 266
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
12 APPENDIX 267
12.1 INSIGHTS OF INDUSTRY EXPERTS 267
12.2 DISCUSSION GUIDE 268
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 272
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 274
12.5 AVAILABLE CUSTOMIZATIONS 276
12.6 RELATED REPORTS 277
12.7 AUTHOR DETAILS 278

* indicates required information

* indicates required information


Share this Product


More from this collection